Together, the present data show that expanding the application of PARP inhibitors beyond breast cancer with BRCA1 mutations (irrespective of BRCA1 status) and optimizing combinative treatment using PARP inhibitors with antimetastasis ruthenium-based chemotherapy could represent a new therapeutic approach for TNBC harboring wild-type BRCA1 [66]. This evidence concerns the gene BRCA1 and breast carcinoma.